Relief Therapeutics completed the acquisition of NeuroX Group.

Relief Therapeutics, a Swiss biopharmaceutical company, completed the acquisition of NeuroX Group, a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases. Financial terms were not disclosed. The transaction establishes a fully integrated company with a first-of-its-kind ecosystem, uniting precision digital neurotherapeutics, pharmacological treatments, cutting-edge devices, data, and an AI-powered platform, positioned to redefine neurological care and change patient lives.